Rep. Carol Devine Miller discloses trade(s) in PFE, DGX, TGT, USB
Carol Devine Miller (WV01) disclosed 4 transactions, traded Mar 10: 0 purchases and 4 sales.
| Traded | Ticker | Company | Action | Amount | Owner |
|---|---|---|---|---|---|
| Mar 10 | PFE | Pfizer, Inc. | Sell | $15,001 - $50,000 | Spouse |
| Mar 10 | DGX | Quest Diagnostics Incorporated | Sell | $15,001 - $50,000 | Spouse |
| Mar 10 | TGT | Target Corporation | Sell | $15,001 - $50,000 | Spouse |
| Mar 10 | USB | U.S. Bancorp | Sell | $15,001 - $50,000 | Spouse |
ORIGINAL FILING ↗ALL FILINGS BY CAROL DEVINE MILLER →CONGRESS TRADES DASHBOARD →
Amounts are the ranges members report. Rows are read automatically from the filing; a trade split across a page break can be missed, so the original filing is the full record.
What This Means
A U.S. representative has filed financial disclosures covering equity transactions in four publicly traded companies spanning pharmaceuticals, healthcare services, retail, and banking. Congressional stock trading disclosures are routine filings required by law and tracked by markets observers and governance advocates as part of broader monitoring of insider trading risk and potential conflicts of interest among lawmakers.
Sources — 1 tier
Every claim below links directly to the original reporting it was drawn from. Penblock synthesizes and cross-references these sources — it doesn't originate the reporting.
- Carol Devine MillerSep 30, 2026Rep. Carol Devine Miller discloses trade(s) in PFE, DGX, TGT, USB ↗
How This Could Play Out — recorded when first flagged, not updated
Resolve
LIKELYNo material market impact; routine disclosure filings are processed as standard governance compliance with no new information about the underlying companies or legislative intent.
Left Unattended
LIKELYThese transactions remain a minor data point in broader congressional trading surveillance, with minimal direct effect on sector or individual stock valuations absent additional context about legislative action or conflict-of-interest concerns.
Escalate
UNLIKELYIf the timing or pattern of these sales were to trigger formal insider-trading investigations or prompt legislative scrutiny of healthcare/financial sector regulation, it could create reputational pressure on the affected companies and heighten governance risk premiums in those sectors.
SPONSORED
Confidence History
- HIGH CONFIDENCESep 30, 2026 at 12:03 PM
Legally mandated financial disclosure filing -- primary source, not a report about the event